Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of Moderate Buy from Analysts

Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price target among […]

Related Keywords

Wisconsin ,United States ,Alan Herman ,Dennism Lanfear ,Doug Farrar ,Steve Glover ,Coherus Biosciences ,Susquehanna Fundamental Investments ,Barclays ,Nasdaq ,Mackenzie Financial Corp ,Coherus Biosciences Company Profile ,Coherus Biosciences Inc ,Group Plc ,Get Rating ,Wisconsin Investment Board ,Fundamental Investments ,General Group Plc ,Financial Corp ,Redwood City ,Coherus Biosciences Daily ,Nasdaq Chrs ,Chrs ,Medical ,Ratings ,Consensus ,